XML 56 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. The Company’s Chief Operating Decision Maker is the Chief Executive Officer (“CEO”). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.
All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.
The following table provides information about the Company’s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes.
Years ended December 31,
202420232022
Net product revenue$169,117 $27,963 $— 
Cost of products sold15,277 846 — 
Gross profit153,840 27,117 — 
Operating expenses:
Research and development expenses15,196 13,261 20,700 
General and administrative expenses84,962 79,596 52,655 
Selling and marketing expenses76,478 56,419 15,291 
Other segment items*19,603 15,690 9,915 
Total operating expenses196,239 164,966 98,561 
Operating loss(42,399)(137,849)(98,561)
Investment and other income (expense), net4,150 87 (536)
Interest expense(10,830)(9,886)(12,342)
Loss on extinguishment of debt— (13,129)— 
Loss before income taxes$(49,079)$(160,777)$(111,439)

*For the years ended December 31, 2024, 2023 and 2022, the other segment items category includes quality and regulatory expenses and medical affairs expenses. For the year ended December 31, 2022, the other segment items category also includes restructuring expense.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill, and operating right-of use-assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2024 and 2023:
Long-lived Assets by Geographic Region: 20242023
U.S.$17,513 $18,413 
Ireland12,210 11,751 
Total$29,723 $30,164 
 
Amortization expense on long-lived assets was immaterial for the years ended December 31, 2024, 2023 and 2022.